Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide

IntroductionTo evaluate counterregulatory hormonal responses during a hypoglycemic clamp with tirzepatide.MethodsParticipants with type 2 diabetes (N=42) were randomized to tirzepatide (15 mg) or placebo for 12 weeks in a crossover design, with a wash-out period of 8–10 weeks. The primary objective...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Thomas R. Pieber, Eva Svehlikova, Shweta Urva, Axel Haupt, Chunmei Zhou, Tamer Coskun, Vera Höller, Gabriele Fluhr, Chrisanthi A. Karanikas, Zvonko Milicevic, Edward John Pratt
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2025-09-01
Reeks:	Frontiers in Endocrinology
Onderwerpen:	type 2 diabetes tirzepatide counterregulatory response hypoglycemia clinical trial
Online toegang:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1627947/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!